Treatment of Post-concussion syndrome with TMS: Using FNIRS as a biomarker of response


Treatment of Persistent Post-Concussion Syndrome with Repetitive Transcranial Magnetic Stimulation: Using Functional Near Infrared Spectroscopy as a Biomarker of Response

PURPOSE: To assess whether repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulation approach, helps your brain to restore appropriate function, and whether functional near-infrared spectroscopy (fNIRS), a neuroimaging technology, can be used to determine your response to this treatment. A secondary question of whether blood biomarkers of inflammation and central nervous system injury change following TMS will also be explored.

WHO: Individuals diagnosed with post-concussion symptoms three months to five years post injury with or without clinical diagnosis of post-traumatic stress disorder.

WHAT: You will receive rTMS treatment for 4 weeks (Monday-Friday, 20 sessions total) at the Foothills Medical Center. Assessments include four questionnaire sessions and four fNIRS and blood collection sessions. Assessments will be scheduled for pre-TMS, post-TMS, 1-month post-TMS, and 3-months post-TMS.

BENEFIT: rTMS treatment may help improve symptoms of concussion such as headache frequency, intensity and duration, concentration, sleep and mood.


Currently recruiting participants: No

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 75

Inclusion criteria:

Eligible participants must meet the following criteria:
1) Age 18-75 years
2) Sustained a concussion/ mild traumatic brain injury (mTBI) >3 months to 5 years ago
3) Persistent symptoms since injury

Exclusion criteria:

Those not eligible for the study:
1) Previous TMS treatment
2) Contraindications to TMS treatments, such as pregnancy, metal fragments or other metal devices in the head, seizure disorders, or medications that would decrease seizure threshold


Sorry, this study is not currently accepting new participants.
Browse other research studies.

Additional information

Contact information

If interested, please contact the study team through

Principal investigator:

Chantel Debert

Clinical trial: